OTCPK:SNZZ.F

Stock Analysis Report

Executive Summary

Senzime AB (publ) develops patient-oriented monitoring systems that assess patients’ biochemical and physiological processes before, during and after surgery in Sweden.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.

Risks

  • Senzime is covered by less than 3 analysts.

Share Price & News

How has Senzime's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

SNZZ.F

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

n/a

SNZZ.F

9.9%

US Medical Equipment

0.7%

US Market

No trading data on SNZZ.F.

No trading data on SNZZ.F.


Share holder returns

SNZZ.FIndustryMarket
7 Day0%1.1%-0.6%
30 Day0%1.3%2.9%
90 Dayn/a3.0%1.3%
1 Yearn/a10.8%9.9%2.9%0.7%
3 Yearn/a70.1%64.9%44.6%35.2%
5 Yearn/a138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Senzime's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Senzime undervalued based on future cash flows and its price relative to the stock market?

4.04x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Senzime's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Senzime's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Senzime is loss making, we can't compare its value to the US Medical Equipment industry average.

Senzime is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Senzime, we can't assess if its growth is good value.


Price Based on Value of Assets

Senzime is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Senzime expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

70.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Senzime's revenue is expected to grow significantly at over 20% yearly.

Senzime's earnings are expected to grow significantly at over 20% yearly.

Senzime's revenue growth is expected to exceed the United States of America market average.

Senzime's earnings growth is expected to exceed the United States of America market average.

Senzime's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Senzime is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Senzime performed over the past 5 years?

-36.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Senzime does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Senzime's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Senzime's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Senzime has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Senzime has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Senzime improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Senzime's financial position?


Financial Position Analysis

Senzime is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Senzime's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Senzime has no debt.

Senzime has no debt compared to 5 years ago when it was 0.4%.


Balance Sheet

Low level of unsold assets.

Senzime has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Senzime has less than a year of cash runway based on current free cash flow.

Senzime has less than a year of cash runway if free cash flow continues to grow at historical rates of 27.9% each year.


Next Steps

Dividend

What is Senzime's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Senzime's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Senzime's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Senzime has not reported any payouts.

Unable to verify if Senzime's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Senzime has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Senzime's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average management tenure


CEO

Pia Renaudin (52yo)

0.6yrs

Tenure

0

Ms. Pia Renaudin serves as Chief Executive Officer at Senzime AB (publ) since February 07, 2019. She has a broad career within the Life Science industry, with global and regional leader positions in Sales  ...


Management Age and Tenure

2.2yrs

Average Tenure

The tenure for the Senzime management team is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

Buykr3,77310 Apr 19
Ulf Lindskog
EntityIndividual
Shares5,000
Max Pricekr0.75
Buykr7,64005 Apr 19
Ulf Lindskog
EntityIndividual
Shares10,000
Max Pricekr0.76
Buykr3,10104 Apr 19
Ulf Lindskog
EntityIndividual
Shares4,000
Max Pricekr0.78
Buykr7,63403 Apr 19
Ulf Lindskog
EntityIndividual
Shares9,900
Max Pricekr0.77
Buykr15,10530 Mar 19
Ulf Lindskog
EntityIndividual
Shares20,015
Max Pricekr0.75
Buykr21,39021 Dec 18
Ulf Lindskog
EntityIndividual
Shares25,000
Max Pricekr0.86
Buykr6,71619 Dec 18
Ulf Lindskog
EntityIndividual
Shares8,119
Max Pricekr0.83
Buykr9,45719 Dec 18
Ulf Lindskog
EntityIndividual
Shares11,425
Max Pricekr0.83
Buykr28,95618 Dec 18
Ulf Lindskog
EntityIndividual
Shares35,923
Max Pricekr0.82

Ownership Breakdown


Management Team

  • Anders Jacobson

    Chief Technology Officer

    • Tenure: 3.8yrs
  • Dave Hampton

    Chief Scientific Officer of Product Development

    • Tenure: 0yrs
  • Rianne Waninge

    Application Scientist

    • Tenure: 0yrs
  • Catrin Molund

    Vice President of Global Marketing & Business Development

    • Tenure: 1.3yrs
    • Compensation: kr87.00k
  • Jessica Roxhed

    Chief Financial Officer

    • Tenure: 3yrs
  • Pia Renaudin (52yo)

    Chief Executive Officer

    • Tenure: 0.6yrs
  • Anders Selin

    Vice President of Global Sales

    • Tenure: 0yrs

Board Members

  • Philip Siberg (46yo)

    Chairman

    • Tenure: 0yrs
    • Compensation: kr100.00k
  • Lennart Kalén (72yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: kr50.00k
  • Adam Dahlberg (46yo)

    Director

    • Tenure: 0yrs
    • Compensation: kr50.00k
  • Sorin Brull (63yo)

    Director

    • Tenure: 0yrs
    • Compensation: kr725.00k

Company Information

Senzime AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Senzime AB (publ)
  • Ticker: SNZZ.F
  • Exchange: OTCPK
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr608.561m
  • Listing Market Cap: kr62.600m
  • Shares outstanding: 49.08m
  • Website: https://www.senzime.com

Location

  • Senzime AB (publ)
  • Ulls väg 29B
  • Uppsala
  • Uppsala County
  • 756 51
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SEZIOM (OMX Nordic Exchange Stockholm)YesClass A SharesSESEKJun 2008
SNZZ.FOTCPK (Pink Sheets LLC)YesClass A SharesUSUSDJun 2008

Biography

Senzime AB (publ) develops patient-oriented monitoring systems that assess patients’ biochemical and physiological processes before, during and after surgery in Sweden. The company offers TetraGraph, a TOF ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:38
End of Day Share Price2019/07/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.